| Species |
Human |
| Protein Construction |
Integrin alpha 2 beta 1 (ITGA2&ITGB1) Heterodimer [Tyr30-T1132(ITGA2) acidic tail & Gln21-Asp728(ITGB1) basic tail]
Accession # P17301-1(ITGA2)&P05556-1(ITGB1) |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
126.6 kDa(ITGA2)&83.2 kDa(ITGB1) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 110-140 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The α2β1 integrin, also known as VLA-2, GPIa-IIa, CD49b, was first identified as an extracellular matrix receptor for collagens and/or laminins. It is now recognized that the α2β1 integrin serves as a receptor for many matrix and nonmatrix molecules. It plays a critical role in platelet function and homeostasis. |
| Synonyms |
α2β1; Integrin alpha A1 beta 1; alpha A1 beta 1; alpha A1; beta 1; ITGA1&ITGB1; ITGA&ITGB; VLA-2, GPIa-IIa, CD49b;Integrin alpha A1 β 1; alpha A1 β 1; β 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
